Reneuron Regulatory News (RENE)

ReNeuron Group plc

("ReNeuron" or "the Company")

ReNeuron makes further senior management appointments

Guildford, UK, 11 June 2015: ReNeuron Group plc (AIM: RENE), a leading UK-based stem cell therapy company, is pleased to announce two further senior management appointments. The appointments are part of a phased restructuring and broadening of the Company's executive and non-executive management as ReNeuron moves into its next phase of development.

Dr Julian Howell will be joining ReNeuron as Chief Medical Officer, with responsibility for clinical development activities at the Company. Dr Howell has held a number of leadership roles in clinical development during the last 15 years, bringing small molecules and biological products through all phases of clinical development in Europe and the US. He joins ReNeuron from Shield Therapeutics, where he held the role of Group Medical Director. Prior to that, Dr Howell led the clinical team at ProStrakan, contributing to multiple US and EU new product approvals in oncology supportive care, GI and pain treatments. He gained medical and surgical qualifications in the UK and worked in the UK health service before completing an MBA at Cranfield University and joining the pharmaceutical industry, initially at SmithKlineBeecham and subsequently in senior clinical and medical affairs roles at Roche, Chiron and Pharmion. 

Shaun Stapleton has been appointed as Head of Regulatory Affairs at ReNeuron. Mr Stapleton joins ReNeuron from RRG (a Voisin Consulting Life Sciences Company) where he was a Director and Vice President of Regulatory Science. He supported clients on a number of global development and registration projects, including advanced therapies and orphan drugs. Having graduated in Biochemistry from Imperial College, London, Mr Stapleton began his career in research with the Imperial Cancer Research Fund, before moving into the pharmaceutical industry. He held positions of increasing responsibility in regulatory affairs at Sterling Winthrop, Eli Lilly and Boehringer Ingelheim before becoming Senior Director of Regulatory Affairs at Ipsen, where he managed regulatory input into development programmes globally, securing new product approvals in the US, EU and internationally in the neurology, endocrinology and oncology therapeutic areas.

Olav Hellebø, Chief Executive Officer of ReNeuron, commented:

"We are delighted to confirm the appointments of Julian and Shaun to our senior management team. Their particular skills, experience and knowledge of the industry will be great assets to the business as we increase our clinical development activities internationally. The appointments further increase the breadth and depth of our executive management team as we evolve and transition the Company into its next stage of development as one of the leading players globally in its field."

Enquiries:

About ReNeuron

ReNeuron is a leading, clinical-stage cell therapy development business. Based in the UK, its primary objective is the development of novel cell-based therapies targeting areas of significant unmet or poorly met medical need.

ReNeuron has used its unique stem cell technologies to develop cell-based therapies for significant disease conditions where the cells can be readily administered "off-the-shelf" to any eligible patient without the need for additional immunosuppressive drug treatments. The Company's therapeutic candidates for stroke disability and critical limb ischaemia are in clinical development and its cell-based treatment for the blindness causing disease, retinitis pigmentosa, is about to enter the clinic in the US.

ReNeuron is also advancing a proprietary platform technology to exploit nanoparticles (exosomes) secreted by stem cells as potential new drug candidates targeting a range of indications including cancer.

ReNeuron's shares are traded on the London AIM market under the symbol RENE.L. Further information on ReNeuron and its products can be found at www.reneuron.com.